By making regulatory flexibilities and coverage policies permanent, policymakers can protect telemedicine as a lasting tool to promote continuous, efficient and patient-centered health care. bit.ly/3g6vWPd

Biologics give patients options. More options can mean lower prices and better health outcomes. Learn more about biologics in BPC's video: bit.ly/2QvCDCs.

Biosimilars are increasing the number of safe, effective treatments for cancer. More treatments mean more opportunities to tailor care. Learn more: bit.ly/3doXVKt.

What’s in a name? Learn about naming conventions for biologics here: bit.ly/2RUApKw.

Non-medical switching happens when an insurer changes a stable patient’s medication to boost profits. It often ends up hurting patients. How? Learn: bit.ly/2wxZQtL.

A patient-centered health care system empowers patients instead of making decisions for them. For too long the system has prioritized disease-centered care. It’s time to shift focus. Learn why: bit.ly/2P1xWfQ.

It’s time to treat patients, not diseases. Learn why patient-centered care makes the most sense for the health care system: bit.ly/3bMMR7I.

Biologics can give patients options. More options can mean lower prices and better health outcomes. Learn more: bit.ly/2QvCDCs.

Biosimilars were first approved by the US FDA five years ago. They are an important part of providers’ therapeutic arsenal to get patients the treatment they need. Find out why providers should embrace biosimilars: bit.ly/371u4nV.

Questions about biologics and endocrinology? Learn about it from Biologics Prescribers Collaborative: bit.ly/3ilId5y

Patient-centered care produces better health outcomes and lower overall costs. Want to know more about why treating individuals and not diseases make more sense to the health care system? Visit ▶️ bit.ly/3bMMR7I

How do biologics, biosimilars, and gastroenterology relate? Biological medications offer innovative treatment options for those with digestive disorders. Want to learn more? Explore this infographic by Biologics Prescribers Collaborative ▶️ bit.ly/2WsZe5B

For patients, non-medical switching affects: 🏥 Health 🏡 Home life 💼 Work life 💚 Emotional well-being Learn more ▶️ bit.ly/2wxZQtL

DYK? Biosimilars are increasing the number of safe, effective treatments for cancer. Arturo Loaiza-Bonilla, MD, and Jeffrey B. VanDeusen, MD, PhD, discuss how policies can ensure biosimilars are accessible for oncologists to personalize care. Read ▶️ bit.ly/3doXVKt

Patient-centered care produces better health outcomes and lower overall costs. Learn more ▶️ bit.ly/3rlvKUl

AfPA's new blog discusses how cancer patients are less comfortable changing from a biologic to a biosimilar medication. It also explains the importance of sharing resources and improving awareness so patients know about their treatment path. Read more ▶️ bit.ly/34V0aUt

Co-pay accumulator adjustment programs mean big setbacks for patients with serious diseases. Learn more ▶️ bit.ly/2T5TNnE

Stay up to date with the National Physicians Biologics Working Group at Alliance for Patient Access.

Join the National Physicians Biologics Working Group at Alliance for Patient Access to stay up to date with the latest in biologics, biosimilars and access.

.AfPA's National Physicians Biologics Working Group is moving to Alliance for Patient Access. Join us there to keep up with all things biologics.